NEOCUTIS® Launches New Product, New Packaging and Snags 20th InStyle Best Beauty Buy Award

NEOCUTIS® AFTERCARE now available to support post-procedure skin regeneration
NEOCUTIS reveals first of new, consumer feedback-driven packaging
Award winning NEOCUTIS earns 20th Best Beauty Buy Award

Merz Americas announced three updates for NEOCUTIS including the launch of NEOCUTIS Aftercare, a post-treatment soothing cream that can enhance post-procedure outcomes; new packaging for best-selling products Lumière, Lumière Riche and Bio Serum; and the recognition from InStyle for the 20th time as a Best Beauty Buy award winner.

“Merz is committed to meeting our customers’ needs, and the latest NEOCUTIS updates further reinforce our commitment to delivering quality skincare options,” said Can Gumus, Vice President of Marketing for Aesthetics at Merz. “I am proud to continue to evolve our NEOCUTIS line with new innovations and quickly react to serve the ever-changing needs of our consumers. NEOCUTIS continues to be an award winning and industry leading skincare line backed by substantial clinical research.”

New Product
NEOCUTIS is the only skincare line founded on clinical research in wound healing.1 The benefits of its newest product, Aftercare, are multifold: skin-regenerating human growth factors boost collagen, comforting emollients help repair skin barrier function, and nourishing vitamins and extracts soothe skin. Neocutis Aftercare provides the skincare patients are seeking for both ablative and nonablative (e.g., microneedling, peels, skin tightening) dermatology treatments. Aftercare will be exclusively available in physician offices.

NEOCUTIS was named one of InStyle’s Best Beauty Buys of 2019 – the 20th consecutive year it has received this recognition. Leading dermatologists, makeup artists and others including InStyle’s own beauty editors, chose this year’s winners to represent what InStyle called “beauty game-changers.” With anti-aging growth factors, moisture-infusing glycerin, and hydrating sodium hyaluronate, Lumière addresses the primary concerns for delicate skin in the eye area.

New Packaging
To help loyal customers and consumers easily identify NEOCUTIS and reduce confusion associated with prior platinum-colored packaging, all NEOCUTIS products will be updated to fresh, signature NEOCUTIS blue packaging. This new packaging reflects today’s contemporary aesthetics and addresses the wants and needs that drive the aesthetics market. The new cartons and bottles are more compact and environmentally friendly while holding the same amount of product. There has been no change to the product formulations.

New packaging is now available for NEOCUTIS Lumière, Lumière Riche and Bio Serum, with more packaging updates to come for other products in the line.

NEOCUTIS products are available for purchase through medical practices and skincare providers. For additional information, or to find an authorized NEOCUTIS skincare provider near you, please visit

REFERENCE: 1. Hohlfeld J, de Buys Roessingh A, Hirt-Burri N, et al. Tissue engineered fetal skin constructs for paediatric burns. Lancet. 2005;366(9488):840-842.

Copyright © 2019 Merz Americas, Inc. All rights reserved. MERZ®, the MERZ® logo, NEOCUTIS® and Lumière® are registered trademarks of Merz Pharma GmbH & Co. KGaA.

Merz Americas
Alison Brown

Press Contact

Merz North America

Emily Browder
Corporate Communications


Phone: +1 919.582.8114

Merz in the Americas

Merz has a direct presence in six countries in the Americas, as well as a network of selected professional distribution partners in South and Central America and the Caribbean. Merz in the Americas is headquartered in Raleigh, North Carolina, and has facilities in Mesa, Arizona, Franksville, Wisconsin as well as offices in Toronto, Canada, Mexico City, Bogotá, Colombia, São Paolo, Brazil and Buenos Aires, Argentina.

Merz Worldwide

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at

Media Contact – Global

Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466

Media Contact – North America

Merz North America, Inc.
Corporate Communications
Emily Browder
Phone: +1 919.582.8114